Medtech regulations in Southeast Asia are at an inflection point. The region is moving toward harmonisation through the ASEAN Medical Device Directive. At the same time, each country maintains its own regulatory authority with distinct timelines, requirements, and implementation practices.
For medical device manufacturers, healthtech firms, and investors, understanding the gap between published regulatory frameworks and operational reality is essential before entering any Southeast Asian market.
In 2025, regulatory harmonisation across Southeast Asia gained momentum, led by the ASEAN Medical Device Directive, which is reshaping the region's medical device landscape by establishing more unified standards for registration, classification, and post-market surveillance.
That harmonisation is real but incomplete. Country-level variation remains significant.
The ASEAN Medical Device Directive was signed in 2015 by all ten member states. The framework ties these markets together through a harmonised risk-based classification system and the adoption of the Common Submission Dossier Template, which standardises registration documentation across the region.
The CSDT simplifies multi-market submissions in principle. In practice, each country interprets and implements the framework at a different pace.
Singapore leads adoption. Singapore's HSA now accepts both the ASEAN CSDT and the IMDRF ToC formats for registration submissions, giving manufacturers flexibility to use the format that best suits their multi-market strategy.
Malaysia is one of the most progressive regulators. Malaysia acceded to MDSAP in September 2025, creating a pathway for manufacturers with MDSAP certification to streamline their Malaysian submissions. Malaysia also updated its ASEAN Medical Device Classification List in July 2025.
The Indonesian government issued the Omnibus Health Law in 2023, which contains incentives for pharmaceutical and medical device manufacturers to conduct research and development activities in Indonesia using local raw materials.
BPOM registration timelines remain among the longest in the region. Recent system upgrades have improved processing speed, but practical timelines for Class B and above devices often exceed published targets.
Regulatory evolution is fast. Malaysia published draft guidance on change management for medical devices in December 2025 and is enforcing mandatory ePermit requirements for all registered medical devices, with full enforcement postponed to July 2027.
The regulatory gateway for the region. Devices approved by HSA are often used as reference for submissions in other ASEAN markets. Singapore introduced a Cybersecurity Labeling Scheme for Medical Devices in March 2025, with other ASEAN regulators expected to follow.
Both markets are implementing AMDD-aligned classification systems. The Philippines FDA received a new Director General in July 2025, which typically signals a period of regulatory priority-setting that affects approval timelines.
For medtech firms planning multi-market entry across Southeast Asia, understanding which regulatory pathways are genuinely fast and which are bottlenecked in practice requires direct practitioner knowledge.
Published regulatory timelines rarely reflect operational reality. Three gaps are most consequential.
Class B and above device registrations in Indonesia, Vietnam, and the Philippines routinely take longer than published targets. Understanding realistic timelines for a specific device category in a specific market requires practitioners who have recently submitted.
AMDD requires post-market surveillance reporting, but enforcement varies significantly. Understanding what regulators are actually prioritising requires current in-market knowledge.
Software as a Medical Device is a fast-moving category across the region. The Philippines published a new medical device software regulation draft in May 2025. How regulators classify and approve digital health tools is evolving faster than any published guide captures.
For Indonesia-specific regulatory research or broader regional market access planning, primary intelligence from practitioners with direct regulatory engagement experience is the most reliable input available.
Connect with Konnect and get matched with the right specialist within 48 hours.
